These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 16771947)

  • 1. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?
    Thabut D; Le Calvez S; Thibault V; Massard J; Munteanu M; Di Martino V; Ratziu V; Poynard T
    Am J Gastroenterol; 2006 Jun; 101(6):1260-7. PubMed ID: 16771947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection.
    Poynard T; Zoulim F; Ratziu V; Degos F; Imbert-Bismut F; Deny P; Landais P; El Hasnaoui A; Slama A; Blin P; Thibault V; Parvaz P; Munteanu M; Trepo C
    Am J Gastroenterol; 2005 Sep; 100(9):1970-80. PubMed ID: 16128941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
    Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
    Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antinuclear antibody is associated with a more advanced fibrosis and lower RNA levels of hepatitis C virus in patients with chronic hepatitis C.
    Hsieh MY; Dai CY; Lee LP; Huang JF; Tsai WC; Hou NJ; Lin ZY; Chen SC; Wang LY; Chang WY; Chuang WL; Yu ML
    J Clin Pathol; 2008 Mar; 61(3):333-7. PubMed ID: 17545561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C.
    Myers RP; Ratziu V; Imbert-Bismut F; Charlotte F; Poynard T;
    Am J Gastroenterol; 2002 Sep; 97(9):2419-25. PubMed ID: 12358267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of ribavirin plus interferon-alpha in patients aged >or=60 years with chronic hepatitis C.
    Honda T; Katano Y; Urano F; Murayama M; Hayashi K; Ishigami M; Nakano I; Yoshioka K; Toyoda H; Kumada T; Goto H
    J Gastroenterol Hepatol; 2007 Jul; 22(7):989-95. PubMed ID: 17608843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural history of hepatic fibrosis progression in chronic hepatitis C virus infection in India.
    Hissar SS; Kumar M; Tyagi P; Goyal A; Suneetha PV; Agarwal S; Rastogi A; Sakhuja P; Sarin SK
    J Gastroenterol Hepatol; 2009 Apr; 24(4):581-7. PubMed ID: 19032460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical response.
    Imai Y; Kasahara A; Tanaka H; Okanoue T; Hiramatsu N; Tsubouchi H; Yoshioka K; Kawata S; Tanaka E; Hino K; Hayashi K; Tamura S; Itoh Y; Sasaki Y; Kiyosawa K; Kakumu S; Okita K; Hayashi N
    J Gastroenterol; 2004 Nov; 39(11):1069-77. PubMed ID: 15580400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Changes in socio-economics, quality of life and knowledge of patients with chronic hepatitis C during the Hepatitis Competence Net Project].
    Niederau C; Bemba G; Kautz A
    Z Gastroenterol; 2008 Jan; 46(1):22-33. PubMed ID: 18188813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study.
    Bonny C; Fontaine H; Poynard T; Hézode C; Larrey D; Marcellin P; Bourlière M; Bronowicki JP; Merle P; Zarski JP; Sapey T; Guillemard C; Ughetto S; Henquell C; Nicolas C; Roche C; Randl K; Bommelaer G; Abergel A
    Aliment Pharmacol Ther; 2006 Aug; 24(4):593-600. PubMed ID: 16907892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults.
    Sulkowski MS; Mehta SH; Torbenson MS; Higgins Y; Brinkley SC; de Oca RM; Moore RD; Afdhal NH; Thomas DL
    AIDS; 2007 Oct; 21(16):2209-16. PubMed ID: 18090048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Artificial neural network model is superior to logistic regression model in predicting treatment outcomes of interferon-based combination therapy in patients with chronic hepatitis C.
    Wang CH; Mo LR; Lin RC; Kuo JJ; Chang KK; Wu JJ
    Intervirology; 2008; 51(1):14-20. PubMed ID: 18309244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 24-week course of high-dose interferon-alpha plus ribavirin for Taiwanese chronic hepatitis C patients with persistently normal or near-normal alanine aminotransferase levels.
    Yu ML; Dai CY; Lee LP; Hou NJ; Hsieh MY; Huang JF; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
    Liver Int; 2006 Dec; 26(10):1187-95. PubMed ID: 17105583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of diet on liver fibrosis and on response to interferon therapy in patients with HCV-related chronic hepatitis.
    Loguercio C; Federico A; Masarone M; Torella R; Blanco Cdel V; Persico M
    Am J Gastroenterol; 2008 Dec; 103(12):3159-66. PubMed ID: 18786125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Biochemical and histologic changes in patients with chronic hepatitis C under treatment with interferon. a 5-year cohort study].
    Dávila-Fernández BC; Santiago-Luna E; Navarro-López R; Moreno Villa HR; Cumplido-Hernández G
    Rev Gastroenterol Mex; 2003; 68(1):16-22. PubMed ID: 12940094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis.
    Roche B; Sebagh M; Canfora ML; Antonini T; Roque-Afonso AM; Delvart V; Saliba F; Duclos-Vallee JC; Castaing D; Samuel D
    Liver Transpl; 2008 Dec; 14(12):1766-77. PubMed ID: 19025933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Steatosis as a predictive factor for treatment response in patients with chronic hepatitis C.
    Antúnez I; Aponte N; Fernández-Carbia A; Rodríguez-Perez F; Toro DH
    P R Health Sci J; 2004 Jun; 23(2 Suppl):57-60. PubMed ID: 16929588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies.
    Bourliere M; Penaranda G; Renou C; Botta-Fridlund D; Tran A; Portal I; Lecomte L; Castellani P; Rosenthal-Allieri MA; Gerolami R; Ouzan D; Deydier R; Degott C; Halfon P
    J Viral Hepat; 2006 Oct; 13(10):659-70. PubMed ID: 16970597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of metabolic syndrome in the setting of chronic hepatitis C virus infection.
    Hanouneh IA; Feldstein AE; Lopez R; Yerian L; Pillai A; Zein CO; Zein NN
    Clin Gastroenterol Hepatol; 2008 May; 6(5):584-9. PubMed ID: 18455698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.